Literature DB >> 6268999

The site of action of muscle relaxant purine nucleosides.

P J Buckle, I Spence.   

Abstract

The effects of a series of purine nucleosides, including the novel marine natural product 1-methylisoguanosine, have been examined on muscle relaxation in conscious animals and on spinal reflexes and neuromuscular transmission in mice anaesthetized with sodium pentobarbitone. 1-Methylisoguanosine (5--15 mumol kg--1) and 2-chloroadenosine (1--5 mumol kg--1), both of which cause muscle relaxation in conscious animals, depressed both mono- and polysynaptic spinal reflexes but did not affect neuromuscular transmission. At much higher doses (300 mumol kg--1) both compounds did depress neuromuscular transmission. Adenosine and 1-methyladenosine did not produce muscle relaxation in conscious animals and only slightly depressed polysynaptic reflexes at the highest doses tested (300 mumol kg--1). Theophylline 50 mumol kg--1 enhanced polysynaptic reflexes and antagonized the depression of these reflexes by 1-methylisoguanosine. Neither adenosine nor 1-methylisoguanosine affected the development of tension by isolated diaphragm muscles in vitro. It is concluded that the muscle relaxant purine nucleosides 2-chloroadenosine and 1-methylisoguanosine produce their effects primarily by depressing activity in the central nervous system. Transmission at the neuromuscular junction is not affected at doses in the range of those producing muscle relaxation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6268999     DOI: 10.1007/bf00507230

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  13 in total

1.  Adenosine-dependent formation of cyclic AMP in brain slices.

Authors:  H D Mah; J W Daly
Journal:  Pharmacol Res Commun       Date:  1976-02

Review 2.  Physiological roles of adenosine derivatives which are released during neurotransmission in mammalian brain.

Authors:  Y Kuroda
Journal:  J Physiol (Paris)       Date:  1978

3.  Site of action of dantrolene in frog sartorius muscle.

Authors:  J W Putney; C P Biancri
Journal:  J Pharmacol Exp Ther       Date:  1974-04       Impact factor: 4.030

4.  The effect of adenosine and adenine nucleotides on the cyclic adenosine 3', 5'-phosphate content of guinea pig cerebral cortex slices.

Authors:  A Sattin; T W Rall
Journal:  Mol Pharmacol       Date:  1970-01       Impact factor: 4.436

5.  Depression of corticospinal cells by various purines and pyrimidines.

Authors:  J W Phillis; G K Kostopoulos; J J Limacher
Journal:  Can J Physiol Pharmacol       Date:  1974-12       Impact factor: 2.273

6.  The effect of diazepam on spinal cord activities: possible sites and mechanisms of action.

Authors:  P Polc; H Möhler; W Haefely
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

7.  Stimulation of guinea-pig brain adenylate cyclase by adneosine analogues with potent pharmacological activity in vivo.

Authors:  L P Davies; K M Taylor; R P Gregson; R J Quinn
Journal:  Life Sci       Date:  1980-03-31       Impact factor: 5.037

8.  1-Methylisoguanosine: an orally active marine natural product with skeletal muscle and cardiovascular effects.

Authors:  J Baird-Lambert; J F Marwood; L P Davies; K M Taylor
Journal:  Life Sci       Date:  1980-03-31       Impact factor: 5.037

9.  Diazepam potentiation of purinergic depression of central neurons.

Authors:  J W Phillis
Journal:  Can J Physiol Pharmacol       Date:  1979-04       Impact factor: 2.273

10.  The effect of adenosine on the release of the transmitter from the phrenic nerve of the rat.

Authors:  B L Ginsborg; G D Hirst
Journal:  J Physiol       Date:  1972-08       Impact factor: 5.182

View more
  1 in total

1.  The actions of adenosine and some analogues on evoked and potassium stimulated release at skeletal and autonomic neuromuscular junctions.

Authors:  P J Buckle; I Spence
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-05       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.